drugset / Trial / NCT06279533

Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules

NCT06279533

Phase 1 Completed 49 enrolled Vigonvita Life Sciences
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is divided into two parts: the safety, tolerability, pharmacokinetic profiles of LV232 capsules after multiple ascending doses (hereinafter referred to as "PK characteristics of multiple ascending doses study ") and food effect study (hereinafter referred to as "FE study"). A total of 48 subjects are planned to be enrolled. The two parts of the study can be carried out simultaneously, and there is no order requirement.

Timeline

Start
2024-02-27
Primary completion
2024-12-17
Completion
2024-12-17

Drugs

EvaluationDrugModalityDoseRoute
Subject LV232 Unknown 15 mg Oral
Subject LV232 Unknown 20 mg Oral
Subject LV232 Unknown 40 mg Oral
Subject LV232 Unknown 60 mg Oral

Indications

No indication recorded.